{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:05:11Z","timestamp":1791230711339,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"BBSRC","doi-asserted-by":"crossref","award":["BB\/T008741\/1"],"award-info":[{"award-number":["BB\/T008741\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK-PG2018-003"],"award-info":[{"award-number":["ARUK-PG2018-003"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peptides and their mimetics are increasingly recognised as drug-like molecules, particularly for intracellular protein-protein interactions too large for inhibition by small molecules, and inaccessible to larger biologics. In the past two decades, evidence associating the misfolding and aggregation of alpha-synuclein strongly implicates this protein in disease onset and progression of Parkinson\u2019s disease and related synucleinopathies. The subsequent formation of toxic, intracellular, Lewy body deposits, in which alpha-synuclein is a major component, is a key diagnostic hallmark of the disease. To reach their therapeutic site of action, peptides must both cross the blood-brain barrier and enter dopaminergic neurons to prevent the formation of these intracellular inclusions. In this review, we describe and summarise the current efforts made in the development of peptides and their mimetics to directly engage with alpha-synuclein with the intention of modulating aggregation, and importantly, toxicity. This is a rapidly expanding field with great socioeconomic impact; these molecules harbour significant promise as therapeutics, or as early biomarkers during prodromal disease stages, or both. As these are age-dependent conditions, an increasing global life expectancy means disease prevalence is rising. No current treatments exist to either prevent or slow disease progression. It is therefore crucial that drugs are developed for these conditions before health care and social care capacities become overrun.<\/jats:p>","DOI":"10.1186\/s13024-023-00675-8","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T20:01:51Z","timestamp":1699473711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Scott G.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy L.","family":"White Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody M.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"675_CR1","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s Disease in 204 Countries\/Territories from 1990 to 2019. Front Public Health. 2021;9:776847.","journal-title":"Front Public Health"},{"key":"675_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"P Rizek","year":"2016","unstructured":"Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson Disease. CMAJ. 2016;188:1157\u201365.","journal-title":"CMAJ"},{"key":"675_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s Disease. Lancet Neurol. 2021;20:385\u201397.","journal-title":"Lancet Neurol"},{"key":"675_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s Disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"675_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson Disease and the neurobiology of axons. Ann Neurol. 2010;67:715\u201325.","journal-title":"Ann Neurol"},{"key":"675_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"675_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","volume":"364","author":"P Ibanez","year":"2004","unstructured":"Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson\u2019s Disease. Lancet. 2004;364:1169\u201371.","journal-title":"Lancet"},{"key":"675_CR8","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s Disease. Lancet. 2004;364:1167\u20139.","journal-title":"Lancet"},{"key":"675_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. Alpha-synuclein locus triplication causes Parkinson\u2019s Disease. Science. 2003;302:841.","journal-title":"Science"},{"key":"675_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/mds.28534","volume":"36","author":"H Liu","year":"2021","unstructured":"Liu H, Koros C, Strohaker T, Schulte C, Bozi M, Varvaresos S, Ibanez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, et al. A novel SNCA A30G mutation causes familial Parkinson\u2019s Disease. Mov Disord. 2021;36:1624\u201333.","journal-title":"Mov Disord"},{"key":"675_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kruger","year":"1998","unstructured":"Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s Disease. Nat Genet. 1998;18:106\u20138.","journal-title":"Nat Genet"},{"key":"675_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body Dementia. Ann Neurol. 2004;55:164\u201373.","journal-title":"Ann Neurol"},{"key":"675_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mds.25421","volume":"28","author":"S Appel-Cresswell","year":"2013","unstructured":"Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s Disease. Mov Disord. 2013;28:811\u20133.","journal-title":"Mov Disord"},{"key":"675_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e31828727ba","volume":"80","author":"C Proukakis","year":"2013","unstructured":"Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel alpha-synuclein missense mutation in Parkinson Disease. Neurology. 2013;80:1062\u20134.","journal-title":"Neurology"},{"key":"675_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.23894","volume":"73","author":"S Lesage","year":"2013","unstructured":"Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, Pieri L, Madiona K, Durr A, Melki R, et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459\u201371.","journal-title":"Ann Neurol"},{"key":"675_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00401-013-1096-7","volume":"125","author":"AP Kiely","year":"2013","unstructured":"Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s Disease and Multiple System Atrophy? Acta Neuropathol. 2013;125:753\u201369.","journal-title":"Acta Neuropathol"},{"key":"675_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s Disease. Science. 1997;276:2045\u20137.","journal-title":"Science"},{"key":"675_CR18","doi-asserted-by":"publisher","first-page":"2180e2181","DOI":"10.1016\/j.neurobiolaging.2014.03.024","volume":"35","author":"P Pasanen","year":"2014","unstructured":"Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Poyhonen M, Paetau A. Novel alpha-synuclein mutation A53E associated with atypical Multiple System Atrophy and Parkinson\u2019s disease-type pathology. Neurobiol Aging. 2014;35:2180e2181\u20132185.","journal-title":"Neurobiol Aging"},{"key":"675_CR19","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1212\/NXG.0000000000000027","volume":"1","author":"MH Martikainen","year":"2015","unstructured":"Martikainen MH, Paivarinta M, Hietala M, Kaasinen V. Clinical and imaging findings in Parkinson Disease associated with the A53E SNCA mutation. Neurol Genet. 2015;1:e27.","journal-title":"Neurol Genet"},{"key":"675_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neurobiolaging.2017.05.022","volume":"57","author":"H Yoshino","year":"2017","unstructured":"Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson\u2019s Disease. Neurobiol Aging. 2017;57:248. e247-248 e212.","journal-title":"Neurobiol Aging"},{"key":"675_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/neup.12687","volume":"40","author":"A Kapasi","year":"2020","unstructured":"Kapasi A, Brosch JR, Nudelman KN, Agrawal S, Foroud TM, Schneider JA. A novel SNCA E83Q mutation in a case of Dementia with Lewy bodies and atypical frontotemporal lobar degeneration. Neuropathology. 2020;40:620\u20136.","journal-title":"Neuropathology"},{"key":"675_CR22","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/bi991447r","volume":"39","author":"KA Conway","year":"2000","unstructured":"Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson\u2019s Disease are typical amyloid. Biochemistry. 2000;39:2552\u201363.","journal-title":"Biochemistry"},{"key":"675_CR23","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1074\/jbc.M411638200","volume":"280","author":"EA Greenbaum","year":"2005","unstructured":"Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem. 2005;280:7800\u20137.","journal-title":"J Biol Chem"},{"key":"675_CR24","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1021\/bi400999d","volume":"52","author":"D Ghosh","year":"2013","unstructured":"Ghosh D, Mondal M, Mohite GM, Singh PK, Ranjan P, Anoop A, Ghosh S, Jha NN, Kumar A, Maji SK. The Parkinson\u2019s disease-associated H50Q mutation accelerates alpha-synuclein aggregation in vitro. Biochemistry. 2013;52:6925\u20137.","journal-title":"Biochemistry"},{"key":"675_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/jnc.12806","volume":"131","author":"NJ Rutherford","year":"2014","unstructured":"Rutherford NJ, Moore BD, Golde TE, Giasson BI. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J Neurochem. 2014;131:859\u201367.","journal-title":"J Neurochem"},{"key":"675_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41422-018-0075-x","volume":"28","author":"Y Li","year":"2018","unstructured":"Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X. Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897\u2013903.","journal-title":"Cell Res"},{"key":"675_CR27","doi-asserted-by":"crossref","unstructured":"Guerrero-Ferreira R, Taylor NM, Arteni AA, Kumari P, Mona D, Ringler P, Britschgi M, Lauer ME, Makky A, Verasdonck J et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. Elife 2019, 8.","DOI":"10.7554\/eLife.48907"},{"key":"675_CR28","doi-asserted-by":"crossref","unstructured":"Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson\u2019s disease - lessons and emerging principles. Mol Neurodegeneration 2019, 14.","DOI":"10.1186\/s13024-019-0329-1"},{"key":"675_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jnc.14810","volume":"150","author":"D Sulzer","year":"2019","unstructured":"Sulzer D, Edwards RH. The physiological role of alpha-synuclein and its relationship to Parkinson\u2019s Disease. J Neurochem. 2019;150:475\u201386.","journal-title":"J Neurochem"},{"key":"675_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","volume":"39","author":"NP Visanji","year":"2016","unstructured":"Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. Alpha-synuclein-based animal models of Parkinson\u2019s Disease: challenges and opportunities in a new era. Trends Neurosci. 2016;39:750\u201362.","journal-title":"Trends Neurosci"},{"key":"675_CR31","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A. Genetics of Parkinson\u2019s Disease. Cold Spring Harb Perspect Med. 2012;2:a008888.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"675_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","volume":"45","author":"EM Rocha","year":"2022","unstructured":"Rocha EM, Keeney MT, Di Maio R, De Miranda BR, Greenamyre JT. LRRK2 and idiopathic Parkinson\u2019s Disease. Trends Neurosci. 2022;45:224\u201336.","journal-title":"Trends Neurosci"},{"key":"675_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-020-00367-7","volume":"15","author":"P Ge","year":"2020","unstructured":"Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson\u2019s Disease. Mol Neurodegener. 2020;15:20.","journal-title":"Mol Neurodegener"},{"key":"675_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C. Movement Disorder Society Evidence-Based Medicine C: International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s Disease. Mov Disord. 2018;33:1248\u201366.","journal-title":"Mov Disord"},{"key":"675_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","volume":"74","author":"H Grosso Jasutkar","year":"2022","unstructured":"Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting alpha-synuclein for Parkinson\u2019s Disease. Pharmacol Rev. 2022;74:207\u201337.","journal-title":"Pharmacol Rev"},{"key":"675_CR36","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4155\/fmc.10.259","volume":"2","author":"JM Mason","year":"2010","unstructured":"Mason JM. Design and development of peptides and Peptide Mimetics as antagonists for therapeutic intervention. Future Med Chem. 2010;2:1813\u201322.","journal-title":"Future Med Chem"},{"key":"675_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based Drugs. Chem Biol Drug Des. 2013;81:136\u201347.","journal-title":"Chem Biol Drug Des"},{"key":"675_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"M Muttenthaler","year":"2021","unstructured":"Muttenthaler M, King GE, Adams DJ, Alewood PE. Trends in peptide drug discovery. Nat Rev Drug Discovery. 2021;20:309\u201325.","journal-title":"Nat Rev Drug Discovery"},{"key":"675_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:48.","journal-title":"Signal Transduct Target Ther"},{"key":"675_CR40","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2174\/1389203722666210615125852","volume":"22","author":"SS Paul","year":"2021","unstructured":"Paul SS, Biswas G. A Mini-review on the effectiveness of Peptoids as therapeutic interventions against neurodegenerative Diseases. Curr Protein Pept Sci. 2021;22:526\u201333.","journal-title":"Curr Protein Pept Sci"},{"key":"675_CR41","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1517\/17460441.2011.632002","volume":"6","author":"WS Horne","year":"2011","unstructured":"Horne WS. Peptide and peptoid foldamers in medicinal chemistry. Expert Opin Drug Discov. 2011;6:1247\u201362.","journal-title":"Expert Opin Drug Discov"},{"key":"675_CR42","doi-asserted-by":"publisher","first-page":"9906","DOI":"10.1021\/bi060837s","volume":"45","author":"N Kokkoni","year":"2006","unstructured":"Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry. 2006;45:9906\u201318.","journal-title":"Biochemistry"},{"key":"675_CR43","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1021\/bi5001257","volume":"53","author":"N Acerra","year":"2014","unstructured":"Acerra N, Kad NM, Griffith DA, Ott S, Crowther DC, Mason JM. Retro-inversal of Intracellular selected ABeta interacting peptides: implications for a Novel alzheimers Disease Treatment. Biochemistry. 2014;53:2101\u201311.","journal-title":"Biochemistry"},{"key":"675_CR44","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1074\/jbc.M114.620484","volume":"290","author":"H Cheruvara","year":"2015","unstructured":"Cheruvara H, Allen-Baume VL, Kad NM, Mason JM. Intracellular screening of a peptide Library to derive a potent peptide inhibitor of alpha-synuclein aggregation. J Biol Chem. 2015;290:7426\u201335.","journal-title":"J Biol Chem"},{"key":"675_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/febs.16312","volume":"290","author":"JAJ Housmans","year":"2023","unstructured":"Housmans JAJ, Wu G, Schymkowitz J, Rousseau F. A guide to studying protein aggregation. FEBS J. 2023;290:554\u201383.","journal-title":"FEBS J"},{"key":"675_CR46","first-page":"1071","volume":"12","author":"F Rahimi","year":"2009","unstructured":"Rahimi F, Maiti P, Bitan G. Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. J Vis Exp. 2009;12:1071.","journal-title":"J Vis Exp"},{"key":"675_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrd3373","volume":"10","author":"O Kepp","year":"2011","unstructured":"Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011;10:221\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"675_CR48","first-page":"REVIEWS3002","volume":"3","author":"JM George","year":"2002","unstructured":"George JM. The synucleins. Genome Biol. 2002;3:REVIEWS3002.","journal-title":"Genome Biol"},{"key":"675_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u2013U123.","journal-title":"Nature"},{"key":"675_CR50","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1074\/jbc.M411805200","volume":"280","author":"TS Ulmer","year":"2005","unstructured":"Ulmer TS, Bax A, Cole NB, Nussbaum RL. Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem. 2005;280:9595\u2013603.","journal-title":"J Biol Chem"},{"key":"675_CR51","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","volume":"273","author":"WS Davidson","year":"1998","unstructured":"Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443\u20139.","journal-title":"J Biol Chem"},{"key":"675_CR52","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1074\/jbc.M008919200","volume":"276","author":"BI Giasson","year":"2001","unstructured":"Giasson BI, Murray IVJ, Trojanowski JQ, Lee VMY. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2001;276:2380\u20136.","journal-title":"J Biol Chem"},{"key":"675_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature15368","volume":"525","author":"JA Rodriguez","year":"2015","unstructured":"Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, et al. Structure of the toxic core of alpha-synuclein from invisible crystals. Nature. 2015;525:486\u201390.","journal-title":"Nature"},{"key":"675_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neulet.2003.12.077","volume":"359","author":"AM Bodles","year":"2004","unstructured":"Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett. 2004;359:89\u201393.","journal-title":"Neurosci Lett"},{"key":"675_CR55","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1021\/ja075356q","volume":"130","author":"J Madine","year":"2008","unstructured":"Madine J, Doig AJ, Middleton DA. Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR. J Am Chem Soc. 2008;130:7873\u201381.","journal-title":"J Am Chem Soc"},{"key":"675_CR56","doi-asserted-by":"crossref","unstructured":"Brown JWP, Buell AK, Michaels TCT, Meisl G, Carozza J, Flagmeier P, Vendruscolo M, Knowles TPJ, Dobson CM, Galvagnion C. beta-synuclein suppresses both the initiation and amplification steps of alpha-synuclein aggregation via competitive binding to surfaces. Sci Rep-Uk 2016, 6.","DOI":"10.1038\/srep36010"},{"key":"675_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1039\/c6mt00026f","volume":"8","author":"JS McDowall","year":"2016","unstructured":"McDowall JS, Brown DR. Alpha-synuclein: relating metals to structure, function and inhibition. Metallomics. 2016;8:385\u201397.","journal-title":"Metallomics"},{"key":"675_CR58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fnins.2019.00381","volume":"13","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li X, Li JD. The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson\u2019s Diseases. Front Neurosci. 2019;13:381.","journal-title":"Front Neurosci"},{"key":"675_CR59","doi-asserted-by":"publisher","first-page":"e2214652120","DOI":"10.1073\/pnas.2214652120","volume":"120","author":"H Matsui","year":"2023","unstructured":"Matsui H, Ito S, Matsui H, Ito J, Gabdulkhaev R, Hirose M, Yamanaka T, Koyama A, Kato T, Tanaka M, et al. Phosphorylation of alpha-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson\u2019s Disease. Proc Natl Acad Sci USA. 2023;120:e2214652120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"675_CR60","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.","journal-title":"Nat Cell Biol"},{"key":"675_CR61","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1021\/ja043247v","volume":"127","author":"LL Liu","year":"2005","unstructured":"Liu LL, Franz KJ. Phosphorylation of an alpha-synuclein peptide fragment enhances metal binding. J Am Chem Soc. 2005;127:9662\u20133.","journal-title":"J Am Chem Soc"},{"key":"675_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41594-020-0384-x","volume":"27","author":"CPA Doherty","year":"2020","unstructured":"Doherty CPA, Ulamec SM, Maya-Martinez R, Good SC, Makepeace J, Khan GN, van Oosten-Hawle P, Radford SE, Brockwell DJ. A short motif in the N-terminal region of alpha-synuclein is critical for both aggregation and function. Nat Struct Mol Biol. 2020;27:249\u2013.","journal-title":"Nat Struct Mol Biol"},{"key":"675_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3\u201326.","journal-title":"Adv Drug Deliv Rev"},{"key":"675_CR64","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bbrc.2006.08.144","volume":"349","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, Sode K. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun. 2006;349:1139\u201344.","journal-title":"Biochem Biophys Res Commun"},{"key":"675_CR65","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1039\/D2CC00212D","volume":"58","author":"CE Bavinton","year":"2022","unstructured":"Bavinton CE, Sternke-Hoffmann R, Yamashita T, Knipe PC, Hamilton AD, Luo J, Thompson S. Rationally designed helical peptidomimetics disrupt alpha-synuclein fibrillation. Chem Commun (Camb). 2022;58:5132\u20135.","journal-title":"Chem Commun (Camb)"},{"key":"675_CR66","doi-asserted-by":"publisher","first-page":"101563","DOI":"10.1016\/j.xcrp.2023.101563","volume":"4","author":"RM Meade","year":"2023","unstructured":"Meade RM, Allen SG, Williams C, Tang TMS, Crump MP, Mason JM. An N-terminal alpha-synuclein fragment binds lipid vesicles to modulate lipid induced aggregation. cell Rep Phys Sci. 2023;4:101563.","journal-title":"cell Rep Phys Sci"},{"key":"675_CR67","doi-asserted-by":"publisher","first-page":"140826","DOI":"10.1016\/j.bbapap.2022.140826","volume":"1870","author":"JR Horsley","year":"2022","unstructured":"Horsley JR, Jovcevski B, Pukala TL, Abell AD. Designer D-peptides targeting the N-terminal region of alpha-synuclein to prevent parkinsonian-associated fibrilization and cytotoxicity. Biochim Biophys Acta Proteins Proteom. 2022;1870:140826.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"675_CR68","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.abb.2017.09.015","volume":"634","author":"N Rezaeian","year":"2017","unstructured":"Rezaeian N, Shirvanizadeh N, Mohammadi S, Nikkhah M, Arab SS. The inhibitory effects of biomimetically designed peptides on alpha-synuclein aggregation. Arch Biochem Biophys. 2017;634:96\u2013106.","journal-title":"Arch Biochem Biophys"},{"key":"675_CR69","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1096\/fj.03-1346fje","volume":"18","author":"OM El-Agnaf","year":"2004","unstructured":"El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson\u2019s Disease and related disorders. Faseb J. 2004;18:1315\u20137.","journal-title":"Faseb J"},{"key":"675_CR70","doi-asserted-by":"publisher","first-page":"11577","DOI":"10.1039\/C5RA00325C","volume":"5","author":"K Sivanesam","year":"2015","unstructured":"Sivanesam K, Byrne A, Bisaglia M, Bubacco L, Andersen N. Binding interactions of agents that alter alpha-synuclein aggregation. Rsc Adv. 2015;5:11577\u201390.","journal-title":"Rsc Adv"},{"key":"675_CR71","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.1074\/jbc.M809671200","volume":"284","author":"CL Kragh","year":"2009","unstructured":"Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem. 2009;284:10211\u201322.","journal-title":"J Biol Chem"},{"key":"675_CR72","doi-asserted-by":"crossref","unstructured":"De Giorgi F, Laferriere F, Zinghirino F, Faggiani E, Lends A, Bertoni M, Yu X, Grelard A, Morvan E, Habenstein B et al. Novel self-replicating alpha-synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons. Sci Adv 2020, 6.","DOI":"10.1126\/sciadv.abc4364"},{"key":"675_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbrc.2008.01.140","volume":"368","author":"HJ Koo","year":"2008","unstructured":"Koo HJ, Lee HJ, Im H. Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem Biophys Res Commun. 2008;368:772\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"675_CR74","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bbrc.2009.07.083","volume":"387","author":"YS Kim","year":"2009","unstructured":"Kim YS, Lim D, Kim JY, Kang SJ, Kim YH, Im H. beta-sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein. Biochem Biophys Res Commun. 2009;387:682\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"675_CR75","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/cbic.201200478","volume":"13","author":"NP Marotta","year":"2012","unstructured":"Marotta NP, Cherwien CA, Abeywardana T, Pratt MR. O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation. ChemBioChem. 2012;13:2665\u201370.","journal-title":"ChemBioChem"},{"key":"675_CR76","doi-asserted-by":"publisher","first-page":"25109","DOI":"10.1074\/jbc.M003554200","volume":"275","author":"E Hughes","year":"2000","unstructured":"Hughes E, Burke RM, Doig AJ. Inhibition of toxicity in the beta-amyloid peptide fragment beta \u2013 (25\u201335) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem. 2000;275:25109\u201315.","journal-title":"J Biol Chem"},{"key":"675_CR77","doi-asserted-by":"publisher","first-page":"128079","DOI":"10.1016\/j.molstruc.2020.128079","volume":"1211","author":"B Zhou","year":"2020","unstructured":"Zhou B, Wang L, Zhang J, Liu Y, Zhong M. Inhibition of aggregation and toxicity of \u03b1-synuclein in the presence of copper by an N-methylated peptide. J Mol Struct. 2020;1211:128079.","journal-title":"J Mol Struct"},{"key":"675_CR78","doi-asserted-by":"crossref","unstructured":"Sangwan S, Sahay S, Murray KA, Morgan S, Guenther EL, Jiang L, Williams CK, Vinters HV, Goedert M, Eisenberg DS. Inhibition of synucleinopathic seeding by rationally designed inhibitors. Elife 2020, 9.","DOI":"10.7554\/eLife.46775"},{"key":"675_CR79","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1038\/s41467-021-24039-2","volume":"12","author":"J Santos","year":"2021","unstructured":"Santos J, Gracia P, Navarro S, Pena-Diaz S, Pujols J, Cremades N, Pallares I, Ventura S. Alpha-helical peptidic scaffolds to target alpha-synuclein toxic species with nanomolar affinity. Nat Commun. 2021;12:3752.","journal-title":"Nat Commun"},{"key":"675_CR80","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.chembiol.2020.12.010","volume":"28","author":"Z Liang","year":"2021","unstructured":"Liang Z, Chan HYE, Lee MM, Chan MK. A SUMO1-Derived peptide targeting SUMO-Interacting Motif inhibits alpha-synuclein aggregation. Cell Chem Biol. 2021;28:180\u2013190e186.","journal-title":"Cell Chem Biol"},{"key":"675_CR81","doi-asserted-by":"publisher","first-page":"16117","DOI":"10.1074\/jbc.M512757200","volume":"281","author":"CM Hecker","year":"2006","unstructured":"Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem. 2006;281:16117\u201327.","journal-title":"J Biol Chem"},{"key":"675_CR82","doi-asserted-by":"publisher","first-page":"40122","DOI":"10.1074\/jbc.M507059200","volume":"280","author":"J Song","year":"2005","unstructured":"Song J, Zhang Z, Hu W, Chen Y. Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem. 2005;280:40122\u20139.","journal-title":"J Biol Chem"},{"key":"675_CR83","doi-asserted-by":"publisher","first-page":"e13863","DOI":"10.1371\/journal.pone.0013863","volume":"5","author":"R Shaltiel-Karyo","year":"2010","unstructured":"Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, Segal D, Gazit E. Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson\u2019s Disease model flies. PLoS ONE. 2010;5:e13863.","journal-title":"PLoS ONE"},{"key":"675_CR84","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/bi020604a","volume":"42","author":"JY Park","year":"2003","unstructured":"Park JY, Lansbury PT Jr. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson\u2019s Disease. Biochemistry. 2003;42:3696\u2013700.","journal-title":"Biochemistry"},{"key":"675_CR85","doi-asserted-by":"publisher","first-page":"14236","DOI":"10.1002\/chem.201601830","volume":"22","author":"M Chemerovski-Glikman","year":"2016","unstructured":"Chemerovski-Glikman M, Rozentur-Shkop E, Richman M, Grupi A, Getler A, Cohen HY, Shaked H, Wallin C, Warmlander SKTS, Haas E, et al. Self-assembled cyclic D,L-alpha-peptides as generic conformational inhibitors of the alpha-synuclein aggregation and toxicity: in Vitro and mechanistic studies. Chem-Eur J. 2016;22:14236\u201346.","journal-title":"Chem-Eur J"},{"key":"675_CR86","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nchembio.193","volume":"5","author":"JA Kritzer","year":"2009","unstructured":"Kritzer JA, Hamamichi S, McCaffery JM, Santagata S, Naumann TA, Caldwell KA, Caldwell GA, Lindquist S. Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol. 2009;5:655\u201363.","journal-title":"Nat Chem Biol"},{"key":"675_CR87","doi-asserted-by":"publisher","first-page":"166706","DOI":"10.1016\/j.jmb.2020.11.005","volume":"432","author":"RM Meade","year":"2020","unstructured":"Meade RM, Morris KJ, Watt KJC, Williams RJ, Mason JM. The Library Derived 4554\u00a0W peptide inhibits primary nucleation of alpha-synuclein. J Mol Biol. 2020;432:166706.","journal-title":"J Mol Biol"},{"key":"675_CR88","doi-asserted-by":"crossref","unstructured":"Torpey JH, Meade RM, Mistry R, Mason JM, Madine J. Insights into peptide inhibition of alpha-synuclein aggregation. Front NeuroSci 2020, 14.","DOI":"10.3389\/fnins.2020.561462"},{"key":"675_CR89","doi-asserted-by":"crossref","unstructured":"Meade RM, Watt KJC, Williams RJ, Mason JM. A downsized and optimised Intracellular Library-Derived peptide prevents alpha-synuclein primary nucleation and toxicity without impacting upon lipid binding. J Mol Biol 2021, 433.","DOI":"10.1016\/j.jmb.2021.167323"},{"key":"675_CR90","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1021\/acschemneuro.2c00190","volume":"13","author":"KJC Watt","year":"2022","unstructured":"Watt KJC, Meade RM, Williams RJ, Mason JM. Library-Derived peptide aggregation modulators of Parkinson?s Disease Early-Onset ?-Synuclein variants. ACS Chem Neurosci. 2022;13:1790\u2013804.","journal-title":"ACS Chem Neurosci"},{"key":"675_CR91","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1038\/s41467-022-32687-1","volume":"13","author":"SM Ulamec","year":"2022","unstructured":"Ulamec SM, Maya-Martinez R, Byrd EJ, Dewison KM, Xu Y, Willis LF, Sobott F, Heath GR, van Oosten Hawle P, Buchman VL, et al. Single residue modulators of amyloid formation in the N-terminal P1-region of alpha-synuclein. Nat Commun. 2022;13:4986.","journal-title":"Nat Commun"},{"key":"675_CR92","doi-asserted-by":"publisher","first-page":"659926","DOI":"10.3389\/fnmol.2021.659926","volume":"14","author":"B Popova","year":"2021","unstructured":"Popova B, Wang D, Rajavel A, Dhamotharan K, Lazaro DF, Gerke J, Uhrig JF, Hoppert M, Outeiro TF, Braus GH. Identification of two novel peptides that inhibit alpha-synuclein toxicity and aggregation. Front Mol Neurosci. 2021;14:659926.","journal-title":"Front Mol Neurosci"},{"key":"675_CR93","doi-asserted-by":"publisher","first-page":"102688","DOI":"10.1016\/j.jbc.2022.102688","volume":"298","author":"M Pirhaghi","year":"2022","unstructured":"Pirhaghi M, Frank SA, Alam P, Nielsen J, Sereikaite V, Gupta A, Stromgaard K, Andreasen M, Sharma D, Saboury AA, Otzen DE. A penetratin-derived peptide reduces the membrane permeabilization and cell toxicity of alpha-synuclein oligomers. J Biol Chem. 2022;298:102688.","journal-title":"J Biol Chem"},{"key":"675_CR94","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41467-023-37464-2","volume":"14","author":"S Nim","year":"2023","unstructured":"Nim S, O\u2019Hara DM, Corbi-Verge C, Perez-Riba A, Fujisawa K, Kapadia M, Chau H, Albanese F, Pawar G, De Snoo ML, et al. Disrupting the alpha-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson\u2019s Disease. Nat Commun. 2023;14:2150.","journal-title":"Nat Commun"},{"key":"675_CR95","unstructured":"Ikenoue T, Oono M, So M, Yamakado H, Arata T, Takahashi R, Kawata Y, Suga H. A RaPID macrocyclic peptide that inhibits the formation of \u03b1-synuclein amyloid fibrils. ChemBioChem, n\/a:e202300320."},{"key":"675_CR96","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1074\/jbc.M111.221382","volume":"286","author":"HS Joo","year":"2011","unstructured":"Joo HS, Cheung GY, Otto M. Antimicrobial activity of community-associated methicillin-resistant Staphylococcus aureus is caused by phenol-soluble modulin derivatives. J Biol Chem. 2011;286:8933\u201340.","journal-title":"J Biol Chem"},{"key":"675_CR97","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N, et al. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science. 2017;358:1440\u20133.","journal-title":"Science"},{"key":"675_CR98","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood.V97.12.3951","volume":"97","author":"OE Sorensen","year":"2001","unstructured":"Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97:3951\u20139.","journal-title":"Blood"},{"key":"675_CR99","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.4049\/jimmunol.1302005","volume":"191","author":"JM Kahlenberg","year":"2013","unstructured":"Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune Disease. J Immunol. 2013;191:4895\u2013901.","journal-title":"J Immunol"},{"key":"675_CR100","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41380-022-01790-6","volume":"27","author":"X Chen","year":"2022","unstructured":"Chen X, Deng S, Wang W, Castiglione S, Duan Z, Luo L, Cianci F, Zhang X, Xu J, Li H, et al. Human antimicrobial peptide LL-37 contributes to Alzheimer\u2019s Disease progression. Mol Psychiatry. 2022;27:4790\u20139.","journal-title":"Mol Psychiatry"},{"key":"675_CR101","doi-asserted-by":"publisher","first-page":"17606","DOI":"10.1073\/pnas.0903691106","volume":"106","author":"P Desplats","year":"2009","unstructured":"Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein (vol\u00a0106, pg 13010, 2009). Proc Natl Acad Sci USA. 2009;106:17606\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"675_CR102","doi-asserted-by":"publisher","first-page":"12571","DOI":"10.1073\/pnas.0906759106","volume":"106","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Prusiner SB. Is Parkinson\u2019s Disease a prion disorder? Proc Natl Acad Sci USA. 2009;106:12571\u20132.","journal-title":"Proc Natl Acad Sci USA"},{"key":"675_CR103","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","volume":"127","author":"M Mandler","year":"2014","unstructured":"Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s Disease clinical trials. Acta Neuropathol. 2014;127:861\u201379.","journal-title":"Acta Neuropathol"},{"key":"675_CR104","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy Body Disease. PLoS ONE. 2011;6:e19338.","journal-title":"PLoS ONE"},{"key":"675_CR105","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","volume":"32","author":"EJ Bae","year":"2012","unstructured":"Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454\u201369.","journal-title":"J Neurosci"},{"key":"675_CR106","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/ijms14022590","volume":"14","author":"W Yoshida","year":"2013","unstructured":"Yoshida W, Kobayashi N, Sasaki Y, Ikebukuro K, Sode K. Partial peptide of alpha-synuclein modified with small-molecule inhibitors specifically inhibits amyloid fibrillation of alpha-synuclein. Int J Mol Sci. 2013;14:2590\u2013600.","journal-title":"Int J Mol Sci"},{"key":"675_CR107","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s42003-021-01746-6","volume":"4","author":"JW Jin","year":"2021","unstructured":"Jin JW, Fan X, Del Cid-Pellitero E, Liu XX, Zhou L, Dai C, Gibbs E, He W, Li H, Wu X, et al. Development of an alpha-synuclein knockdown peptide and evaluation of its efficacy in Parkinson\u2019s Disease models. Commun Biol. 2021;4:232.","journal-title":"Commun Biol"},{"key":"675_CR108","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22:407\u201317.","journal-title":"Lancet Neurol"},{"key":"675_CR109","doi-asserted-by":"publisher","first-page":"10968","DOI":"10.1038\/s41598-023-37655-3","volume":"13","author":"KJC Watt","year":"2023","unstructured":"Watt KJC, Meade RM, James TD, Mason JM. Development of a hydroxyflavone-labelled 4554\u00a0w peptide probe for monitoring alpha-synuclein aggregation. Sci Rep. 2023;13:10968.","journal-title":"Sci Rep"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-023-00675-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T21:02:05Z","timestamp":1699477325000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-023-00675-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1186\/s13024-023-00675-8","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMM is an advisor to Sapience Therapeutics. The authors declare no other competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}